Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Genetic breakthrough in lung cancer

For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.

16 Dec 2010

Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation

Researchers from Italy determined that radiofrequency ablation (RFA) is a safe and effective therapy for managing hepatocellular carcinoma (HCC) in cirrhotic patients. The high repeatability of RFA is advantageous in controlling recurrences of cancerous tumors in the liver. Results of this 10-year retrospective study are available in the January 2011 issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

16 Dec 2010

RFA highly valuable therapy for controlling cancerous nodules

16 Dec 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.

16 Dec 2010

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals.

16 Dec 2010

Study demonstrates BRACAnalysis testing for women with breast carcinoma in situ

Myriad Genetics, announced today that an article entitled "Prevalence of BRCA1 and BRCA2 Mutations In Women With Carcinoma In Situ of the Breast Referred for Genetic Testing" will appear in the December 2010 issue of the journal Cancer Prevention Research.

16 Dec 2010

Novel adenovirus-based gene therapy for renal cell carcinoma

Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown to kill cancer cells not only at the primary tumor site but also in distant tumors not directly infected by the virus. Renal cell carcinoma is the most common form of kidney cancer in adults and currently there is no effective treatment for the disease once it has spread outside of the kidney.

16 Dec 2010

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).

16 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

Myotec, Hybrid merge to form PsiOxus Therapeutics

Myotec Therapeutics, Ltd. and Hybrid BioSystems, Ltd. today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets.

15 Dec 2010

Chinese hospital uses UNIQUE radiotherapy system to treat cancer patients

Prince of Wales Hospital in Hong Kong, China, has become the first treatment center in Asia to commence treating cancer patients using the UNIQUE™ medical linear accelerator from Varian Medical Systems (NYSE: VAR).

14 Dec 2010

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Shak, MD, chief medical officer of Genomic Health.

14 Dec 2010

Osteoporosis drug reduces bone loss in oral cancer

A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.

14 Dec 2010

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

14 Dec 2010

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

10 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

10 Dec 2010

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that a Phase 3 pivotal study with OncoVEXGM-CSF for the first line treatment of patients with locally advanced squamous cell carcinoma of the head & neck has commenced.

10 Dec 2010

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

10 Dec 2010

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

The sun's ultraviolet light activates an enzyme that helps skin cancer cells survive and proliferate, researchers report.

8 Dec 2010

Carcinoma News and Research

Further Reading

Genetic breakthrough in lung cancer

Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation

RFA highly valuable therapy for controlling cancerous nodules

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

Study demonstrates BRACAnalysis testing for women with breast carcinoma in situ

Novel adenovirus-based gene therapy for renal cell carcinoma

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Myotec, Hybrid merge to form PsiOxus Therapeutics

Chinese hospital uses UNIQUE radiotherapy system to treat cancer patients

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

Osteoporosis drug reduces bone loss in oral cancer

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News